#ESCCongress – M-A | Polipílulas com e sem aspirina reduziram sobremaneira a ocorrência de doença cardiovascular, infarto do miocárdio, AVC, revascularização e morte por causa cardiovascular na prevenção primária de doença cardiovascular.
2 Set, 2021 | 11:06hFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Comentário: Combo therapy cuts risk of heart attacks and strokes in half – McMaster University
Conteúdos relacionados:
Opinion: A new important study supports wider use of the polypill
Perspective: Are Polypills and Population-based Treatment the Next Big Things?
The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era
Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population
Perspective: The Polypill and the Long Journey to Major Impact
Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care